Oncolytics Biotech Inc. (NASDAQ:ONCY) Sees Significant Increase in Short Interest

Oncolytics Biotech Inc. (NASDAQ:ONCY) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 2,650,000 shares, an increase of 159.8% from the September 30th total of 1,020,000 shares. Based on an average trading volume of 405,900 shares, the short-interest ratio is currently 6.5 days.

Oncolytics Biotech Stock Down 2.4 %

NASDAQ:ONCY traded down $0.03 on Friday, reaching $1.22. 430,465 shares of the company’s stock traded hands, compared to its average volume of 326,325. The stock has a 50-day simple moving average of $1.04 and a 200-day simple moving average of $1.05. The firm has a market cap of $93.10 million, a PE ratio of -4.07 and a beta of 1.79. Oncolytics Biotech has a 12 month low of $0.84 and a 12 month high of $1.80.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. During the same period in the prior year, the firm earned ($0.09) EPS. On average, equities analysts anticipate that Oncolytics Biotech will post -0.29 earnings per share for the current year.

Institutional Investors Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC acquired a new stake in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech at the end of the most recent reporting period. 6.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research note on Thursday, September 19th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.